Brand name · Paricalcitol
Zemplar: adverse event reports filed with FDA
11,348 reports list it as a suspect or interacting product, 2004–2026. Class: Vitamin D analog. Also reported as Zemplar Capsules 1mcg, Zemplar Capsules 2mcg, Zemplar Injection.
- 11,348
- reports as suspect product
- 0.1% of all reports · about 516 a year
- 5
- reports, 12 months to June 2026
- 6 in the 12 months before
- 93.6%
- marked serious by the reporter
- 87.8% across the class
- 70%
- record death among outcomes, as reported
- 7,947 reports · not verified by FDA
11,348 adverse event reports received by FDA list the brand name Zemplar (paricalcitol) as a suspect or interacting product, from July 2004 to February 2026. A further 1,823 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 5 reports listed it, down 17% from 6 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 516 reports a year and 0.1% of the 20,646,523 reports in the database, and 91.2% of the reports for the vitamin D analog class. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are death (30.3%), cardiac disorder (5.3%) and myocardial infarction (4.7%). A report can list several reactions, so shares add to more than 100%; 624 different terms appear across these reports. Death is recorded in 30.3% of these reports, a larger share than in the median vitamin D analog drug (15.2%).
93.6% of the reports are marked serious by the reporter (87.8% across the class); 70% record death among the outcomes and 23.2% record hospitalisation, as reported. 53.6% of the reports came from physicians, and the largest patient age group is 45 to 64 (17.1%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Zemplar reports recording the termmedian drug in vitamin d analog
- Deaththe patient died; cause not stated by this term30.3%3,439
- Cardiac disorder5.3%601
- Myocardial infarctionheart attack4.7%537
- Cardio-respiratory arrestthe heart and breathing stopped3.8%436
- Sepsisa severe body-wide response to infection3.5%396
- Cardiac failureheart failure2.7%301
- Infarction2.2%253
- Cerebrovascular accidentstroke2.2%247
- Dyspnoeashortness of breath1.9%220
- Cardiac arrestthe heart stopped1.9%213
- Adverse eventan unwanted medical event, type not specified1.7%194
- Pneumonialung infection1.7%189
- Respiratory arrestbreathing stopped1.7%188
- Infectionan infection, type not specified1.6%185
- Falla fall1.6%176
- General physical health deteriorationgeneral decline in health1.5%168
- Acute myocardial infarction1.4%164
- Renal transplant1.4%157
- Pyrexiafever1.4%156
- Cardiovascular disorder1.3%151
- Astheniaweakness or lack of energy1.2%141
- Fatiguetiredness1.2%139
- Malaisegeneral feeling of being unwell1.2%132
- Vomitingbeing sick1.1%127
- Diarrhoealoose or frequent stools1.1%124
- Dizzinesslight-headedness or unsteadiness1.1%120
- Pulmonary oedemafluid in the lungs1%115
- Unevaluable eventthe event could not be assessed1%115
- Headachehead pain1%112
- Painpain, site not specified1%112
Top 30 of 624 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 2 drugs in the vitamin d analog class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 12,441 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 9.3% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Hyperparathyroidism secondary | 3,090 | 27.2% |
| Nephropathy | 2,543 | 22.4% |
| Renal failure | 2,272 | 20% |
| Renal failure chronic | 939 | 8.3% |
| Hyperparathyroidism | 546 | 4.8% |
| Chronic kidney disease | 337 | 3% |
The indication field is filled in by the reporter and is often blank; shares are of all 11,348 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Zemplar reports |
|---|---|---|
| Folic acid | 362 | 3.2% |
| Omeprazole | 313 | 2.8% |
| Furosemide | 296 | 2.6% |
| Amlodipine | 275 | 2.4% |
| Losartan | 274 | 2.4% |
| Aspirin | 242 | 2.1% |
| Carvedilol | 227 | 2% |
| Clonidine | 211 | 1.9% |
| Allopurinol | 177 | 1.6% |
| Metoprolol | 165 | 1.5% |
Other products listed in reports where Zemplar is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Zemplar | Vitamin D analog | All reports |
|---|---|---|---|
| Reports as suspect product | 11,348 | 12,441 | 20,646,523 |
| Share of that pool | — | 91.2% | 0.1% |
| Reports, latest 12 months | 5 | — | 1,332,454 |
| Marked serious | 93.6% | 87.8% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 700 | 640 | 91 |
| Hospitalisation recorded, per 1,000 reports | 232 | 217 | 213 |
| Consumer-filed share | 26.1% | 25% | 45.8% |
| Top term, share of reports | Death 30.3% | median 15.2% | 4.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the vitamin d analog class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Calcipotriene | generic | 1,093 | 83 | 27.4% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Zemplar reports
How many adverse event reports has FDA received for Zemplar?
11,348 reports list Zemplar as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 5 of them arrived in the latest 12 months. Another 1,823 list it only as a concomitant medication.
What reactions are recorded in Zemplar reports?
death (30.3%), cardiac disorder (5.3%), myocardial infarction (4.7%), cardio-respiratory arrest (3.8%) and sepsis (3.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Zemplar was responsible.
How serious are the reports?
93.6% are marked serious by the reporter. Among the outcomes recorded, 70% of reports include death and 23.2% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (53.6%), consumer or non-health professional (26.1%) and other health professional (13.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Zemplar rising?
5 reports in the 12 months to June 2026, down 17% from 6 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Zemplar was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Zemplar?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zemplar as a suspect or interacting product; reports listing it only as a concomitant medication (1,823) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.